BVS vs NVCR vs NKTR vs MASI

For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.

3% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Bioventus Inc. (BVS) offers the better valuation at 25. 8x trailing P/E (11. 0x forward), making it the more compelling value choice. Analysts rate Bioventus Inc. (BVS) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Bioventus Inc.

is actually cheaper at 11. 0x.

Over the past 5 years, Masimo Corporation (MASI) delivered a total return of -16.

2%, compared to -91. 6% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: MASI returned +258. 8% versus NKTR's -72. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Masimo Corporation (MASI) is the lower-risk stock at 0.

44β versus NovoCure Limited's 2. 24β — meaning NVCR is approximately 405% more volatile than MASI relative to the S&P 500. On balance sheet safety, Masimo Corporation (MASI) carries a lower debt/equity ratio of 78% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.

3% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Bioventus Inc. grew EPS 163. 5% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, NVCR leads at 6. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bioventus Inc.

(BVS) is the more profitable company, earning 4. 0% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 4. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MASI leads at 20. 5% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bioventus Inc.

(BVS) trades at 11. 0x forward P/E versus 32. 5x for Masimo Corporation — 21. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NKTR: 130. 6% to $149. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Masimo Corporation (MASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

44), +258. 8% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MASI: +258. 8%, NVCR: +53. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.